SCHEMBL2547604

SCHEMBL2547604

COCCn1c(-c2c[nH]c(-c3ccc(Cl)c(OC)c3)n2)nc2ccc(C)cc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.47
▸ HSD17B10 Q99714 2/20 0.47
▸ RECQL P46063 1/20 0.47
▸ ALDH1A1 P00352 4/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ CASR P41180 5/20 0.39
▸ HPGD P15428 2/20 0.38
▸ ALOX5 P09917 1/20 0.37
▸ EPHX2 P34913 1/20 0.37
▸ BRD4 O60885 2/20 0.36
▸ PTGER4 P35408 3/20 0.35
▸ TP53 P04637 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ GLA P06280 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12286455 0.89 CASR (0.39) KDM4EHSD17B10RECQLALDH1A1SMN1; SMN2
SCHEMBL14575975 0.88 RIPK2 (0.43) KDM4EHSD17B10RECQLALDH1A1SMN1; SMN2
SCHEMBL2555448 0.83 KDM4E (0.39) KDM4EHSD17B10RECQLALDH1A1SMN1; SMN2
SCHEMBL12286421 0.81 PTGER4 (0.52) KDM4EHSD17B10RECQLPTGER4RIPK2
SCHEMBL12283727 0.81 PTGER4 (0.53) KDM4EHSD17B10RECQLPTGER4RIPK2
SCHEMBL14576869 0.80 KDM4E (0.49) KDM4EHSD17B10RECQLALDH1A1SMN1; SMN2
SCHEMBL2554816 0.80 KDM4E (0.37) KDM4EHSD17B10RECQLALDH1A1SMN1; SMN2
SCHEMBL14575950 0.80 RIPK2 (0.49) KDM4EHSD17B10RECQLALDH1A1SMN1; SMN2
SCHEMBL2554431 0.75 HPGD (0.57) KDM4EHSD17B10RECQLALDH1A1SMN1; SMN2
SCHEMBL2551496 0.75 PTGER4 (0.54) PTGER4RIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US claimed
EP-2552208-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS Glaxo Group Limited (GB) 2013-02-06 — — EP disclosed
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed
WO-2011123609-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2011-10-06 — — WO disclosed
WO-2011123609-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2011-10-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS MAP3K19, MAP3K20, MAP3K3 KDM4E 764/4885HSD17B10 3817/4885RECQL 1347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback